Get the Stockscreener App
22.71
3.03%
-0.71
After Hours:
22.71
Urogen Pharma Ltd stock is traded at $22.71, with a volume of 430.13K.
It is down -3.03% in the last 24 hours and down -6.85% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$23.42
Open:
$23.7
24h Volume:
430.13K
Relative Volume:
0.42
Market Cap:
$1.06B
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-6.188
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
-1.39%
1M Performance:
-6.85%
6M Performance:
+75.23%
1Y Performance:
+112.24%
1-Day Range:
$22.44
$23.81
1-Week Range:
$22.44
$23.81
52-Week Range:
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
22.71 | 1.10B | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
The Truth About UroGen Pharma (URGN): Is This Tiny Cancer Stock the Next Viral Game-Changer or a Tot - AD HOC NEWS
What analysts say about UroGen Pharma Ltd stockMarket Timing Techniques & Free High Velocity Capital Growth - earlytimes.in
The Technical Signals Behind (URGN) That Institutions Follow - Stock Traders Daily
URGN: Small-Cap Biotech On A Knife Edge As Traders Weigh Risk, Cash And Uro-Oncology Data - AD HOC NEWS
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - AOL.com
Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance
What drives UroGen Pharma Ltd stock priceBreakout Stock Watch & Free Exceptional Market Positioning - earlytimes.in
Chemo Pharma Laboratories Limited Stock Fails to Break Resistance Traders ReactMarket Liquidity Analysis & Low Risk Capital Gains - bollywoodhelpline.com
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - The Motley Fool
What analysts say about UroGen Pharma Ltd UR8 stockGlobal Trade Effects & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Trading Systems Reacting to (URGN) Volatility - news.stocktradersdaily.com
Why UroGen Pharma Ltd. stock appeals to analystsQuarterly Profit Report & Accurate Intraday Trading Signals - Улправда
Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC - MarketBeat
Volume Report: What valuation multiples suggest for UroGen Pharma Ltd. stock2025 Market WrapUp & Long Hold Capital Preservation Tips - Улправда
Can UroGen Pharma Ltd. stock surprise with earnings upsideJuly 2025 Levels & Real-Time Market Trend Scan - Улправда
Can UroGen Pharma Ltd. stock deliver sustainable ROEPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - Улправда
How UroGen Pharma Ltd. (UR8) stock trades in high volatility2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
US Stocks Recap: Will UroGen Pharma Ltd. (UR8) stock benefit from Fed rate cuts2025 Fundamental Recap & Intraday High Probability Setup Alerts - Улправда
Is UroGen Pharma Ltd. stock oversold or undervaluedWeekly Market Report & Weekly Market Pulse Alerts - Улправда
Aug Shorts: Will UroGen Pharma Ltd. stock see insider buyingPortfolio Profit Report & Real-Time Volume Surge Alerts - Улправда
What valuation multiples suggest for UroGen Pharma Ltd. stockJuly 2025 Trade Ideas & Daily Stock Trend Reports - Улправда
FOMO Trade: Why UroGen Pharma Ltd. stock appeals to analystsPortfolio Value Summary & Risk Controlled Stock Alerts - Улправда
Urogen Pharma Target of Unusually Large Options Trading (NASDAQ:URGN) - MarketBeat
Q2 2025 Urogen Pharma Ltd Earnings Call Transcript - GuruFocus
Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.4%Still a Buy? - MarketBeat
Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Acorn Capital Advisors LLC Has $17.26 Million Stock Holdings in Urogen Pharma $URGN - MarketBeat
Avoiding Lag: Real-Time Signals in (URGN) Movement - news.stocktradersdaily.com
Earnings Recap: Is UroGen Pharma Ltd stock trading at a premium valuation2025 Earnings Surprises & Low Risk Profit Maximizing Plans - moha.gov.vn
Menora Mivtachim Holdings LTD. Reduces Holdings in Urogen Pharma $URGN - MarketBeat
Urogen Pharma $URGN Shares Purchased by Diadema Partners LP - MarketBeat
Urogen Pharma milestone: First patient treated with new cancer medication - Traders Union
Walleye Capital LLC Takes Position in Urogen Pharma $URGN - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma - The National Law Review
UroGen Pharma (URGN) Issues Stock Units to New Employees - GuruFocus
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - simplywall.st
Panagora Asset Management Inc. Acquires 168,908 Shares of Urogen Pharma $URGN - MarketBeat
Is UroGen Pharma Ltd. (UR8) stock prepared for digital transition2025 Biggest Moves & Free Reliable Trade Execution Plans - Newser
What margin trends mean for UroGen Pharma Ltd. stockJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - Newser
Why UroGen Pharma Ltd. (UR8) stock signals breakout potentialJuly 2025 Fed Impact & Fast Gain Swing Trade Alerts - Newser
Urogen Pharma (NASDAQ:URGN) Trading Down 6.1%What's Next? - MarketBeat
UroGen Pharma Ltd (URGN) Stock Price, Trades & News - GuruFocus
Muscle Invasive Bladder Cancer Market to Reach New Heights - openPR.com
Can UroGen Pharma Ltd. (UR8) stock test all time highs2025 Price Targets & Free Verified High Yield Trade Plans - Newser
UroGen Pharma (URGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Piper Sandler Healthcare Conference - marketscreener.com
Discipline and Rules-Based Execution in URGN Response - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Entropy Technologies LP Buys New Shares in Urogen Pharma $URGN - MarketBeat
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - ADVFN
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):